Pharmaceuticals, Biotechnology and Life Sciences
CYNK-101 is an investigational genetically modified NK cell therapy designed to synergize with antibody therapeutics for difficult to treat cancers…
TEL AVIV, Israel and NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology…
– More than 70 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; enrollment complete and regulatory…
Orphazyme A/SCompany announcementNo. 05/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 15, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”),…
BOSTON, Feb. 15, 2022 (GLOBE NEWSWIRE) — Radius Health, Inc. (NASDAQ: RDUS) announced today that it will release its fourth…
MAINZ, Germany, February 15, 2022 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will welcome project partners, among them…
Completed acquisition of BayMedica, a rare cannabinoid manufacturing and commercialization company in the health and wellness sectorStrengthened IP with patent…
SHANGHAI, China, Feb. 15, 2022 (GLOBE NEWSWIRE) — ECMOHO Limited (Nasdaq: MOHO) (“ECMOHO” or the “Company”), an integrated solutions provider…
– Bavdegalutamide demonstrated a 46% PSA50 rate in patients with metastatic castration-resistant prostate cancer (mCRPC) and androgen receptor (AR) T878X/H875Y…
Five year follow-up data show FOTIVDA® (tivozanib) patients up to 5X more likely to experience long-term PFS compared to Nexavar®…